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TaqI Polymorphism of the Vitamin-D Receptor Gene and
Quality of Life in Postmenopausal Turkish Women
Aim: We aimed to assess vitamin-D receptor (VDR) gene polymorphism in postmenopausal osteoporotic
Turkish women as well as the impact of this on diagnosis, treatment and quality of life.
Materials and Methods: Seventy postmenopausal osteoporotic women and 71 postmenopausal healthy
women constituted the disease and control groups, respectively. Genomic DNA was extracted from blood of
all participants and analyzed for the TaqI gene polymorphism of the VDR gene. The osteoporotic group was
taking calcitonin, alendronate, calcitriol and elementary calcium, while the control group was taking only
vitamin D and calcium. Quality of life of patients was measured by Nottingham Health Profile (NHP). Bone
mineral density (BMD) was measured using DEXA method.
Results: Genotype distribution of disease and control subjects, respectively, were as follows: TT (28.6%;
42.3%), Tt (62.8%; 40.8%), and tt (8.6%; 16.9%). Tt genotype was significantly higher in the study group
(P < 0.005). There were no significant differences between the distribution of TT and tt genotypes between
groups. However, BMD scores were significantly higher in the subjects with active T allele. There were also
significant differences in before and after treatment NHP scores (p:0.001).
Conclusions: Frequency of Tt variant was found higher in the disease group. The NHP score was significantly
lower after treatment. Presence of T allele leads to higher BMD values than observed with t allele. The genetic
variations with respect to polymorphism of the VDR gene may be important in determining the diagnosis,
treatment outcome and quality of life in osteoporosis.
Key Words: Osteoporosis, quality of life, TaqI polymorphism, vitamin D receptor gene

Postmenapozal Türk Kad›nlardaki Vit D Reseptör Genindeki Taq I Polimorfizmi
ve Yaﬂam Kalitesi
Amaç: Postmenapozal osteoporozu olan kad›nlardaki olas› VDR gen polimorfizminin tan›, tedavi ve yaﬂam
kalitesi üzerindeki etkilerini araﬂt›rmakt›r.
Yöntem ve Gereç: Yetmiﬂ postmenapozal kad›n hasta grubunu ve 71 postmenapozal sa¤l›kl› kad›n kontrol
grubunu oluﬂturdu. Çal›ﬂmaya kat›lan tüm bireylerin kan örneklerinden genomik DNA izole edilerek VDR
geninin Taq I polimorfizmi analiz edildi. Hasta grubuna salmon kalsitonin 200 IU (2 ay) ve alendronat 70 mg
haftada, calcitriol 1 g/gün ve elementar calcium 1000 mg/gün verildi. Kontrol grubuna ise calcium 1000 mg
ve 880 mg D vitamini verildi. Yaﬂam Kalitesi Nothingham Sa¤l›k profili (NHP) ile de¤erlendirildi. Tedavi öncesi
ve sonras› vertebra ve femur kemik mineral yo¤unlu¤u DEXA yöntemi ile ölçüldü.
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Bulgular: Hasta ve kontrol grubunu genotip da¤›l›m› s›ras› ile TT (% 28,6; % 42,3), Tt (% 62,8; % 40,8),
tt (% 8,6; % 16,9) olarak saptand›. Çal›ﬂma grubunda Tt genotipleri kontrol grubuna oranla anlaml› olarak
yüksekti. (P < 0.005). “TT ve Tt” genotiplerin da¤›l›m›na iliﬂkin gruplar aras›nda anlaml› bir fark saptanmad›.
Ancak T allelini etkin olarak taﬂ›yan olgularda, kemik BMD ve DEXA de¤erlerinin anlaml› olarak daha iyi oldu¤u
gözlendi. Olgular›n tedavi öncesi ve sonras› yaﬂam kalitesi skorlar› aras›nda anlaml› fark oldu¤u gözlendi
(p:0.001).
Sonuç: “Tt” variant›n›n hastalarda anlaml› olarak yüksek oldu¤u saptand›. Yaﬂam kalitesinin tedavi öncesi ve
sonras› skorlar›n›n da anlaml› olarak düﬂtü¤ü gözlendi. T allelinin varl›¤›n›n kemik BMD ve DEXA de¤erlerinde
t alleline göre anlaml› olarak daha iyi oldu¤u gözlendi. Osteoporoz hastalar›nda VDR gen polimorfizminin
saptanmas›, hastalar›n tan›s›nda, tedavinin planlanmas›nda ve yaﬂam kalitesinin de¤erlendirilmesinde önemli
oldu¤u kan›s›na var›ld›.
Anahtar Sözcükler: Osteoporoz, Yaﬂam kalite, TaqI polimorfizmi, Vitamin D reseptör geni
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Introduction
Osteoporosis (OP) is a common disease associated
with reduced bone mineral density, affecting up to 40%
of women at some point during their life span. Although
OP is a multifactorial disease, genetic factors play an
important role in its pathogenesis (1-3).
Although a strong association between vitamin-D
receptor (VDR) genotype and bone mineral density (BMD)
was suggested in OP (4,5), there are conflicting findings
on the possible association between postmenopausal bone
loss and the VDR genotype (6,7). The association of VDR
genotype and BMD may be different in various ethnic and
geographical groups (8-10). Therefore, we assume that it
would be worthwhile to assess the VDR polymorphism
among the Turkish population.
The action of vitamin D depends on the functional
status of the VDR, which has polymorphic variants. The
original claim that the polymorphic variation at the VDR
locus may account for up to 75% of the genetic
contribution to bone mass has been contested, with
subsequent work yielding conflicting data (4,11).
OP interferes with the patient’s quality of the life. The
Nottingham Health Profile (NHP) is widely accepted as a
useful index for the generic health status measures, and
possibly to assess quality of life in OP patients (12).
The purpose of this study was to assess the TaqI
polymorphism on the VDR gene among Turkish
osteoporotic women in view of its importance in the
diagnosis and treatment of OP as well as on the quality of
life of these patients.

Materials and Methods
Seventy women with postmenopausal OP who
consecutively admitted to our Physical Medicine and
Rehabilitation Clinic were included into this study. Their
ages ranged from 46 to 69 years (mean 60.5 ± 5.5). The
diagnosis of OP in the study group was made according
to BMD values of the patients detected in the lumbar and
hip regions.
OP was diagnosed according to the World Health
Organization (WHO) criteria (13). The BMD, expressed as
density of the area in grams per square centimeter, was
measured in the anterior-posterior lumbar spine (L2-4)
and femur with dual-energy X-ray absorptiometry
(DEXA) using a QDR-1500 Hologic instrument.
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Seventy-one healthy postmenopausal women whose
ages ranged from 44 to 69 years (mean 60.4 ± 5.2)
were also included in the study and comprised the control
group. Their BMD values were less than –1 SD and more
than – 2.5 SD that of healthy young adult women (14).
The routine laboratory investigations (complete blood
count, blood chemistry, thyroid function tests) were
performed in both groups. None of the subjects had bone
fractures related to OP or any other disease that might
affect the bone metabolism.
The serum estradiol (E2) levels of the patients and the
control subjects were less than 30 pg/ml. Their
postmenopausal periods ranged from 3 to 17 years
(mean 8.8 ± 2.9) in study group and 2 to15 years in
controls (mean 7.4 ± 3.2).
One of the standard therapy protocols was
administered to the patients in the study group and
consisted of intranasal salmon calcitonin 200 IU/day (total
2 months), alendronate 70 mg/week, elementary Ca
1000 mg/day and calcitriol 1 µg/day. The subjects in the
control group were given 1000 mg elementary Ca 1000
mg/day and 880 IU vitamin D orally. Both groups were
advised to undertake regular exercise daily and to
increase their dietary intake of milk or milk products.
The NHP is a questionnaire that helps to assess
quality of life. It is a widely accepted outcome
measurement, and has also been validated in our country.
Briefly, NHP is comprised of 38 statements (answered
"yes" or "no") that assess subjective distress in six
sections. The scores for each section range from 0 (no
problem) to 100 (all problems listed are present) (12).
Since it would be difficult to separate emotional reactions
and social isolation statements in our population,
assessment of the latter was not performed. The NHP
questionnaire was applied twice for each patient, with the
first application before initiation of the medical therapy
and the second at the 8th month of therapy.
Molecular Analysis
DNA extraction and analysis
After obtaining informed consent, blood samples were
drawn from each subject. Venous blood samples were
collected in ethylenediaminetetraacetic acid (EDTA)
containing tubes. DNA was extracted from whole blood
by salting out procedure (6).
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Genotypic analysis of polymorphisms of the VDR
gene
The genotype for four restriction fragment length
polymorphisms (RFLP) of the VDR gene was determined
by polymerase chain reaction (PCR) amplification and
enzymatic digestion of the products with ApaI, BsmI, TaqI
and FokI.
A region of the receptor gene carrying the three
reported polymorphic restriction sites ApaI, BsmI, TaqI
[situated in intron 8 and the 5’ end of exon 9; 2000 base
pairs (bp)] was amplified by PCR.
The specific primers for the VDR were upstream
primer
positioned
in
exon
8
(5’CAACCAAGACTACAAGTACCGCGTCAGTGA-3’)
and
downstream primer positioned in exon 9 (5’CACTTCGAGCACAAGGGGCGTTAGC-3’).
PCR
was
performed in a 50 µL volume with 20-100 ng DNA, 100
µm dNTPs, 20 pmol of each primer, 1 mM MgCl2, 1x PCR
buffer with (NH4)2SO4 and 1U Taq polymerase (MBI
Fermentas, Vilnius, Lithuania). Amplification was
performed on an automated Thermal Cycler (Techne
Genius, Cambridge, England). PCR conditions were 3 min
for initial denaturation at 94.5°C; 35 cycles at 94.5°C for
1 min for denaturation, 1 min at 61°C for annealing and 2
min at 72°C for extension, followed by 7 min at 72°C for
final extension. With the enzymes ApaI, BsmI and TaqI,
respective genotypes were defined as A, B, T (indicating
the absence of the restriction site) or a, b, t (indicating the
presence of restriction site). The digest products were
resolved at 100 V for 20-30 min on a 1.5% agarose gel
containing 0.5 µg/ml ethidium bromide. A 100 bp marker
(100 bp DNA Ladder, MBI Fermentas, Vilnius, Lithuania)
was used as a size standard for each gel lane. The gel was
visualized under UV light using a gel electrophoresis
visualizing system (Vilber Lourmat, France).
PCR product for ApaI, BsmI and TaqI polymorphism
was 2000 bp long; the lengths of the fragment and
genotyping after digestion for 3 h at 30°C with ApaI
(Roche Molecular Biochemicals, GmbH, Germany),
digestion for 3 h at 37°C with BsmI isoschizomer
Mva1269I (MBI Fermentas, Vilnius, Lithuania) and
digestion for 3 h at 65°C TaqI (MBI Fermentas, Vilnius,
Lithuania) were AA 2000 bp; Aa 2000 bp, 1700 bp and
300 bp; aa 1700 bp and 300 bp; BB 2000 bp; Bb 2000
bp, 1350 bp and 650 bp; bb 1350 bp and 650 bp; TT
2000 bp; Tt 2000 bp, 1800 bp and 200 bp; tt 1800 bp
and 200 bp.
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In addition, another polymorphism (FokI) of the VDR
gene was analyzed in our study. The primers and PCR
conditions for amplifying exon 2 of the VDR gene were
described previously [7-9]. The primers 5’AGCTGGCCCTGGCACTGACTCTGCTCT-3’
and
5’ATGGAAACACCTTGCTTCTTCTCCCTC-3’ were used to
amplify exon 2. PCR was performed in a 25 µL volume
with 20-100 ng DNA, 100 µm dNTPs, 20 pmol of each
primer, 1 mM MgCl2, 1x PCR buffer with (NH4)2SO4 and
1U Taq polymerase. After amplification PCR products
were digested by restriction endonuclease FokI
isoschizomer BseGI (MBI Fermentas, Vilnius, Lithuania)
for 3 h at 55°C, the genotyping of VDR gene was
determined by fragment separation on a 3% agarose gel.
The genotypes were classified as: FF, homozygotes,
absence of the Fok I site results in one fragment of 265
bp; Ff, heterozygotes exhibiting fragments of 265 bp,
196 bp, and 69 bp; ff, homozygotes, presence of the site
results in two fragments of 196 bp and 69 bp.
Statistical Analyses
The data were analyzed using SPSS 13.0 for
Windows. The associations of BMD and the other
parameters in each VDR genotype were assessed using
ANOVA. ANOVA and paired t test were used to compare
NHP scores and VDR genotype.

Results
There were no significant differences in the
demographic data between the groups (P > 0.05). The
demographic data and T-scores are shown in Table 1.
Table 1. Demographic data and DEXA values.
Parameters

Patients

Controls

Age (year)
BMI (m/kg2)
VBMD
FBMD
WBMD
TS
TF
TW

60.5 ± 5.50
31.7 ± 4.50
0.98 ± 0.20
0.87 ± 0.20
0.63 ± 0.16
-2.8 ± 1.40
-2.2 ± 1.30
-2.7 ± 1.20

60.4 ± 5.2
32.5 ± 4.5
1.1 ± 0.12
0.9 ± 0.12
0.7 ± 0.10
-0.5 ± 1.0
-0.8 ± 0.9
-0.7 ± 0.9

BMI: Body mass index. VBMD: BMD value of spine. FBMD: BMD value of
femur. WBMD: BMD value of Wards triangle of femur. Ts: DEXA-T value
of spine. TF: DEXA-T value of femur. TW: DEXA-T value of Wards
triangle of femur.
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The VDR genotype distribution in patients and control
groups were TT (28.6%; 42.3%), Tt (62.8%; 40.8%),
and tt (8.6%; 16.9%), respectively. There was a
significant difference in the Tt genotype between patients
and controls (P < 0.05), with the Tt genotype
overrepresented in the study group (Table 2). Genotyping
was based upon independent scoring of the outcomes by
two reviewers who were unaware of the case/control
status (Figure 1).

Table 2. Results of molecular analyses of VDR gene polymorphism.
Genotype

Turk J Med Sci

The differences between frequencies of TT and tt
variants in patients and controls were not significant. To
understand which allele (T or t) was of importance with
respect to OP and quality of the life, we compared total
T and t alleles between the patient and control groups,
and the difference again was not significant (p: 0.246).
However, we believe that presence of T alleles has a
positive effect on BMD and DEXA values as well as quality
of life. Presence of tt genotype did not have a positive
effect on bone or on the quality of life. This may be
interpreted as the feature of tt genotype or may have
been due to the limited number of the patients or
controls who had it (Table 3).

TT

Tt*

tt

Patients (n)
(%)

20
(28.6%)

44
(62.8%)

6
(8.6%)

NHP parameters were significantly lower after the
therapy when compared to values before the treatment
(P < 0.001) (Table 4).

Controls (n)
(%)

30
(42.3%)

29
(40.8%)

12
(16.9%)

Discussion
Osteoporosis, which has become an important issue in
this century as a consequence of improved health care,
may be considered a complex interaction between subtle
genetic polymorphisms and environmental influences
(16). The presence of familial concordance of OP appears
to be suggestive of a genetic basis (17,18).

* The difference was significant, P < 0.05.

Figure 1. TaqI polymorphism of vitamin-D receptor gene of groups.

The VDR is involved in the regulation of calcium
homeostasis in many tissues (1). It is known that there
are three polymorphic sites, BsmI, ApaI and TaqI, on the
VDR gene (2,19). In a study regarding TaqI
polymorphism, the frequencies of the different forms of
the VDR genotypes were found to be 39.5%, 41%, and
19.5%, for the TT, Tt and tt variants, respectively (20).
In our study, however, the frequencies of TT, Tt and tt
variants were 28.6%, 62.8% and 8.6% in the study
group, and 42.3%, 40.8%, 16.9% in the control group,
respectively. The data above indicate that the frequency
of each genotype varies between different populations.

Table 3. Results of multiple comparisons between genotype subgroups, BMD and T-scores in the patient group.
Comparison of Genotype

VBMD

FBMD

WBMD

Ts

TF

TW

TT-Tt

P: 0.001

P: 0.001

P: 0.001

P: 0.001

P: 0.001

P: 0.001

TT-tt

P: 0.001

P: 0.004

P: 0.001

P: 0.001

P: 0.006

P: 0.001

Tt-tt

P: 0.419

P: 0.956

P: 0.680

P: 0.364

P: 0.962

P: 0.726

VBMD : BMD value of spine. FBMD : BMD value of femur. WBMD: BMD value of Wards triangle of
femur. Ts: T-score of spine. TF : T-score of femur. TW : T value of Wards triangle of femur.
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Table 4. Results of before and after therapy NHP scores according to subgroups of genotype.
NHP Parameters

Pain

Fatigue

Physical Activities

Sleeping

Emotional Reactions

Subgroups of
Genotype

Before Therapy
NHP Scores

After Therapy
NHP Scores

TT

67.4 ± 6.2

35.9±4.7

Tt

76.4 ± 5.5

37.8 ± 4.0

tt

75.0 ±7.8

36.7 ± 2.6

TT

67.4 ±6.2

35.7 ± 4.7

Tt

76.4 ± 4.8

36.6 ± 4.9

tt

77.5 ±8.8

37.5 ±4.2

TT

66.1 ± 5.2

36.3 ± 5.7

Tt

74.1 ± 5.1

35.6 ± 4.9

tt

75.8 ± 3.8

36.7 ± 4.1

TT

68.9 ± 5.8

34.4 ± 4.1

Tt

74.7 ± 4.9

33.1 ± 6.1

tt

74.2 ± 2.1

36.7 ± 2.6

TT

67.1 ± 5.8

37.8 ± 4.0

Tt

75.2 ± 5.3

36.6 ± 5.2

tt

74.8 ± 3.6

36.7 ± 2.8

It was shown that the bone densities did not differ
according to TaqI genotype. In addition, there was a
trend toward higher values for vertebral and femoral
bone density in girls with the “TT” genotype and toward
lower values in girls with the homozygous “tt” genotype
(21). However, we found a significant difference in
frequency of “Tt” variants between the patients and
controls.
The BMD values were reported to be low in subjects
with the tt genotype (15). It was suggested that BMD
scores of subjects with TT genotype are better than those
with Tt genotype (22). We found that the influence of
variants of TT-Tt and TT-tt, which consisted mainly of
“T” alleles, was significantly better than that of the
variants of Tt-tt, which consisted of mainly “t” alleles, on
all BMD and DEXA values (Table 4). This condition may
also be interpreted by ethnic diversity.
In our study, all patients who had all genotypes had
significant improvement in the quality of life as
determined by NHP scores. There was no significant

difference between genotypes of the patients on the
quality of life as determined by NHP scores.
Previous studies addressed mainly VDR gene
polymorphism and BMD changes. However, to our
knowledge, this is the first study in which the quality of
life was assessed as a function of VDR gene
polymorphism. Although we determined a significant
difference in distribution of the Tt genotype between
groups, there was no impact of this on evaluation of
health quality and treatment. This may be associated with
the limited number of cases. However, patients with the
“t” allele should be given particular attention with respect
to treatment and prophylaxis of OP.
In conclusion, genetic variations may be important in
determining the treatment outcome in OP, such as the
polymorphism of the VDR gene that codes for calciumrelated receptors. The genetic patterns of the patients
may be of importance both in treatment planning and
patient evaluation in OP.
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